Imatinib-d8

CAT: 0804-HY-15463S-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-15463S-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Imatinib-d8 is a deuterium labeled Imatinib (STI571) . Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].
CAS Number
[1092942-82-9]
Product Name Alternative
STI571-d8; CGP-57148B-d8
UNSPSC
12352005
Target
Autophagy; Bcr-Abl; c-Kit; PDGFR; SARS-CoV
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection; Autophagy; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
99.88
Solubility
10 mM in DMSO|DMSO : 12.5mg/mL (ultrasonic) |H2O : 10mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
O=C(NC1=CC=C(C)C(NC2=NC=CC(C3=CC=CN=C3)=N2)=C1)C4=CC=C(CN5C([2H])([2H])C([2H])([2H])N(C)C([2H])([2H])C5([2H])[2H])C=C4
Molecular Formula
C29H23D8N7O
Molecular Weight
501.65
References & Citations
[1]Heinrich MC, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000 Aug 1;96 (3) :925-32.|[2]Guida T, et al. Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants. Clin Cancer Res. 2007 Jun 1;13 (11) :3363-9.|[3]Coleman CM, et al, Frieman MB. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion. J Virol. 2016;90 (19) :8924‐8933. Published 2016 Sep 12.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products